Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects (STEPS)

Patient enrollment has begun in a Phase 3 registration study to confirm previously reported data that demonstrated GATTEX(TM) (teduglutide) was well tolerated and reduced parenteral nutrition (PN) dependence in short-bowel syndrome (SBS) patients. The international, double-blind, placebo-controlled safety and efficacy study of GATTEX is known as STEPS (Study of TEduglutide in PN-dependent Short-bowel syndrome).
For more information on STEPS, please click here.

Use of NPSP558 in the Treatment of Hypoparathyroidism (REPLACE)

Patient enrollment has begun in a Phase 3 registration study, known as REPLACE, evaluating NPSP558, our proprietary recombinant, full-length (1-84), human parathyroid hormone, for the treatment of hypoparathyroidism.  The primary objective is to demonstrate, over a 24-week treatment period, that once-daily subcutaneous dosing with NPSP558 at doses of 50µg, 75µg or 100µg is a safe and effective hormone replacement therapy for the treatment of patients with hypoparathyroidism.
For more information on REPLACE, please click here.